Global Alliance for Infections in Surgery

Better understanding of the mechanisms of antibiotic resistance

ACT NOW
Antibiotic prescribing practices in surgery

Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanisms of antibiotic resistance</td>
<td>4</td>
</tr>
<tr>
<td>Antibiotic resistance in Enterobacteriaceae</td>
<td>9</td>
</tr>
<tr>
<td>Antibiotic resistance in non-fermenting Gram-negative bacteria</td>
<td>14</td>
</tr>
<tr>
<td>New antibiotics against Gram-negative bacteria</td>
<td>18</td>
</tr>
<tr>
<td>Antibiotic resistance in enterococci</td>
<td>21</td>
</tr>
<tr>
<td>Antibiotic resistance in <em>Staphylococcus aureus</em></td>
<td>23</td>
</tr>
<tr>
<td>Long-Acting Lipoglycopeptides</td>
<td>26</td>
</tr>
<tr>
<td>AWaRe classification</td>
<td>27</td>
</tr>
</tbody>
</table>
Preface

Better understanding of mechanisms of antibiotic resistance would allow the development of control strategies to reduce the spread of resistant bacteria and their evolution.

Antimicrobial resistance (AMR) is not a disease for which we should expect ultimately to develop a cure. Instead it is a silent pandemic that is here to stay. AMR is a phenomenon where microorganisms adapt through evolution to survive the onslaught of antimicrobial drugs. It undermines the treatment of many common diseases as well as standard surgical procedures. It is a challenge to global development. Antimicrobial effectiveness must be looked upon as a limited global public good on the verge of becoming scarce, and the world has a collective responsibility to preserve it in order to avoid countless future victims of multidrug-resistant infections. In the face of such problem, everyone must contribute. Now, more than ever, one world, one medicine, one health...

Massimo Sartelli
acting director
Global Alliance for Infections in Surgery
Mechanisms of antibiotic resistance
Beginning with the discovery of penicillin by Alexander Fleming in the late 1920s, antibiotics have revolutionized the field of medicine. They have saved millions of lives each year. However, we have now reached a crisis where many antibiotics are no longer effective. Such infections often result in an increased number of hospitalizations, more treatment failures and the persistence of drug-resistant pathogens. Better understanding of mechanisms of antibiotic resistance would allow the development of control strategies to reduce the spread of resistant bacteria and their evolution. Bacteria may be intrinsically resistant to a class of antibiotics or may acquire resistance. Main mechanisms of resistance to antibiotics can be caused by:

Alteration of the target site of the antibiotic. A common strategy for bacteria to develop antimicrobial resistance is to avoid the action of the antibiotic by interfering with their target site. To achieve this, bacteria have evolved different tactics, including protection of the target (avoiding the antibiotic to reach its binding site) and modifications of the target site that result in decreased affinity for the antibiotic molecule.

Enzyme inactivation of the antibiotic. One of the most successful bacterial strategies to cope with the presence of antibiotics is to produce enzymes that inactivate the drug by adding specific chemical moieties to the compound or that destroy the molecule itself, rendering the antibiotic unable to interact with its target.

Active transport of the antibiotic out of the bacterial cell. The production of complex bacterial machineries capable to extrude a toxic compound out of the cell can also result in antimicrobial resistance. Many classes of efflux pumps have been characterized in both Gram-negative and Gram-positive pathogens.

Decreased permeability of the bacterial cell wall to the antibiotic. Many of the antibiotics used in clinical practice have intracellular bacterial targets or, in case of Gram-negative bacteria, located in the cytoplasmic membrane (the inner membrane). Therefore, the compound must penetrate the outer and/or cytoplasmic membrane in order to exert its antimicrobial effect. Bacteria have developed mechanisms to prevent the antibiotic from reaching its intracellular or periplasmic target by decreasing the uptake of the antimicrobial molecule.
Bacteria can develop resistance to antibiotics by mutating existing genes (vertical evolution), or by acquiring new genes from other strains or species (horizontal gene transfer).

Many of the antibiotic mobile resistance genes (MGEs) are carried on genetic elements (plasmids, transposons or phages) that act as vectors that transfer these genes to other members of the same bacterial species, as well as to bacteria in another genus or species.

The MGEs allow resistance to spread horizontally and disseminate among different bacterial species. Although this association seems improbable, it appears to occur frequently and follows a series of evolutionary steps fueled by natural selection (antibiotic selection). The power of modern DNA sequence analysis allows us to better understand the process of emergence of these genetic structures. The primary mechanisms of horizontal transfer are conjugation (plasmids are transferred from a donor cell to a recipient cell), transformation (uptake of naked DNA), and transduction (bacteriophages as transporters of genetic information). Conjugation is considered the principal mode for antibiotic resistance transfer, because many resistance genes are situated on mobile elements, such as plasmids integrons and transposons.
Most families of antibiotics present in nature are compounds produced by fungi or bacteria; bacteria utilize these compounds to eliminate competitor microorganisms. As part of this arms race, many microorganisms code for genes whose products neutralize antibiotics; these genes may have been present in bacterial chromosomes for millions of years and they were probably not mobile, as evidenced by recent findings. The massive use of antibiotics probably favored selection of antibiotic resistant bacteria resulting in large numbers of bacteria coding for resistance genes. On the other hand, bacterial chromosomes are populated with transposable elements (insertion sequences known as ISs), which jump frequently and randomly, as demonstrated during in vitro experiments from one genetic location to another in the same cell. Antibiotic resistance genes could be mobilized to genetic structures, such as plasmids and phages, which can move horizontally between bacterial cells including different bacterial species. The association of resistance genes to these mobile structures could occur through ISs; this has been postulated as the origin of many MGEs. Alternatively, plasmids or phages may also integrate in the bacterial chromosome in the vicinity of resistance genes and then mobilize the resistance genes as these structures excise from chromosomes. Emergence of resistance among the most important bacterial pathogens is recognized as a major public health threat affecting humans worldwide. Widespread use of antibiotics has undoubtedly facilitated the development of antimicrobial resistance worldwide. Better understanding of the mechanisms of antibiotic resistance, will help clinicians regarding usage of antibiotics in different situations.
Antibiotic resistance in Enterobacterales
Antibiotic resistance to beta-lactam agents

Beta-lactam antibiotics exhibit the most common treatment for bacterial infections and continue to be the prominent cause of resistance to beta-lactam antibiotics among Gram-negative bacteria worldwide. The persistent exposure of bacterial strains to a multitude of beta-lactams has induced dynamic and continuous production and mutation of beta-lactamases in these bacteria, expanding their activity against most beta-lactam antibiotics.

Resistance to beta-lactams in *Enterobacterales* is mainly conferred by beta-lactamases. These enzymes inactivate beta-lactam antibiotics by hydrolysis. Beta-lactamases are commonly classified according to two systems: the Ambler molecular classification and the Bush–Jacoby–Medeiros functional classification. The Ambler scheme classifies beta-lactamases into four classes according to the protein homology of enzymes. Beta-lactamases of class A, C, and D are serine beta-lactamase and class B enzymes are metallo-beta-lactamases. The Bush–Jacoby–Medeiros functional scheme is based on functional properties of enzymes and on their ability to hydrolyze specific beta-lactam classes. This classification was updated in 2010. The updated system includes group 1 (class C) cephalosporinases; group 2 (classes A and D) broad-spectrum, inhibitor-resistant, extended-spectrum beta-lactamases and serine carbapenemases; and group 3 (class B) metallo-beta-lactamases.

Group 1 enzymes are cephalosporinases belonging to molecular class C. They are more active on cephalosporins than benzylpenicillin. It includes AmpC beta-lactamases. AmpC-hyperproducing mutants are resistant to penicillins, aztreonam, third generation cephalosporins including cefotaxime, ceftazidime, ceftriaxone and even ertapenem when the enzyme is massively expressed. Cefepime, a fourth-generation cephalosporin with broader spectrum activity compared to ceftriaxone, is a poor inducer of AmpC beta-lactamase. Many AmpC-producing organisms are susceptible to cefepime because cefepime is poorly hydrolyzed by the AmpC beta-lactamase enzyme. However, the role of cefepime in treating infections caused by AmpC-producing organisms is controversial because of the inoculum effect.
Group 2 (classes A and D) represent the largest group of beta-lactamases, it includes ESBL producing *Enterobacterales* and carbapenemases (class A) and OXA beta-lactamases (class D).

ESBL are enzymes capable of hydrolyzing and inactivating a wide variety of beta-lactams, including third-generation cephalosporins, penicillins, and aztreonam. Most ESBLs of clinical interest are encoded by genes located on plasmids. These plasmids may also carry genes encoding resistance to other multiple drug classes including aminoglycosides and fluoroquinolones. The main ESBL enzymes imparting antibiotic resistance are TEM-, SHV-, and CTX-M.

Risk factors of ESBL producing *Enterobacterales* include recent exposure to antibiotics (particularly third-generation cephalosporins or fluoroquinolones) and known colonisation with ESBL producing *Enterobacterales*.

Carbapenems have been considered the empiric antibiotics of choice for treating patients with ESBL-producing *Enterobacterales*. Group 1 carbapenems include ertapenem—a once-a-day carbapenem sharing the same activity of Group 2 carbapenems against ESBL-producing *Enterobacterales*. However, it is not active against *Pseudomonas aeruginosa* and enterococci. Group 2 includes imipenem/cilastatin, meropenem, and doripenem. Compared to ertapenem, they have activity against non-fermentative Gram-negative bacilli. Unlike meropenem and doripenem, imipenem/cilastatin is active against enterococci that are susceptible to ampicillin. However, in order to avoid excessive carbapenem use, carbapenem-sparing strategies using other antibiotics—such as piperacillin/tazobactam, an aminoglycoside agent, tigecycline, or eravacycline—should be considered. The significance of piperacillin/tazobactam for treating ESBL-producing *Enterobacterales* has been a debated issue. Gram-negative bacteria have the ability to concomitantly produce multiple ESBLs as well as AmpC beta-lactamases and can possess other mechanisms of resistance limiting the activity of piperacillin/tazobactam. On the other hand, the activity of piperacillin/tazobactam is influenced by the “inoculum effect”—a laboratory phenomenon described as a significant increase in the MIC of an antibiotic when a great number of bacteria are inoculated.

An RCT conducted in patients with ESBL-producing *Enterobacterales* bloodstream infections demonstrated inferior results of piperacillin/tazobactam compared to carbapenems.
Although piperacillin/tazobactam is not considered the first-choice antibiotic to treat ESBL-producing *Enterobacterales*, it may still be considered a valuable carbapenem-sparing agent in the management of ESBLs in some settings like intra-abdominal infections treated with adequate source control when dealing with fully susceptible bacteria (MIC ≤ 8 mg/L). A high dose (18 g) should be prescribed to optimise PK/PD targeting in critically ill patients. Aminoglycosides have in vitro activity against aerobic Gram-negative bacteria, including ESBL-producing *Enterobacterales*, and act synergistically against certain Gram-positive bacteria. Because of their serious toxic side effects, including nephrotoxicity and ototoxicity, some authors do not recommend aminoglycosides for the routine empiric treatment. They may be reserved for patients with allergies to beta-lactam agents or used in combination with beta-lactam agents. In any case, this class of antibiotics remains an important option to treat Gram-negative bacteria and widen the spectrum of antibiotic therapy when resistant organisms are suspected. Tigecycline remains a useful option for treating patients with complicated intra-abdominal infections or soft tissue infections, due to its favourable activity against anaerobic organisms, enterococci, and ESBLs. It has no in vitro activity against *P. aeruginosa* or certain *Enterobacterales*, including *Proteus* spp. and *Serratia* spp. Excess mortality was observed in patients treated with tigecycline when compared with other antibiotics. Study-level and patient-level analyses demonstrated that, in particular, patients with ventilator-associated pneumonia and baseline bacteraemia were at a higher risk of mortality. A mortality analysis was used to investigate the association of baseline factors with clinical failure and mortality in complicated IAIs and did not suggest that tigecycline was a factor either for failure or for death in phase 3 and 4 comparative clinical trials of tigecycline. Tigecycline should not be considered the first-line option for treating hospital-acquired pneumonia and bacteraemia.
Rates of CTX-M infections have increased during the last decade compared with rates of TEM- and SHV- infections. The diffusion of CTX-M-producing Enterobacteriaceae are common in Southeast Asia and Eastern Mediterranean countries.

The OXA-type beta-lactamases are so named because of their oxacillin-hydrolyzing abilities. OXA beta-lactamases have resistance limited to the penicillins, but some became able to confer resistance to cephalosporins. OXA-1 and OXA-10 beta-lactamases have only a narrow hydrolytic spectrum. However, other OXA beta-lactamases including OXA-11, -14, -15, -16, -28, -31, -35 and -45 confer resistance to cefotaxime, ceftazidime and aztreonam. OXA-23 and OXA-48 are classes of carbapenemases that belong to OXA-type beta-lactamases with carbapenem-hydrolyzing activities. While OXA-23 appears most frequently in A. baumannii, OXA-48 enzymes have now become widespread in the Enterobacteriaceae, especially in Mediterranean countries.

*K. pneumoniae* carbapenemases (KPCs) are beta-lactamases produced by Gram-negative bacteria. They efficiently hydrolyse penicillins, all cephalosporins, monobactams, beta-lactamase inhibitors, and even carbapenems. KPCs are becoming an increasingly significant problem worldwide. KPC-producing *K. pneumoniae* pose a serious threat in clinical situations where administration of effective empiric antibiotics is essential to prevent mortality following bacteraemia and infections in immunocompromised patients including organ transplant recipients and those with cancer.

Group 3 (Class B) metallo-beta-lactamases (MBLs) differ structurally from the other beta-lactamases by their requirement for a zinc ion at the active site. They are all capable of hydrolysing carbapenems. In contrast to the serine beta-lactamases, the MBLs have poor affinity or hydrolytic capability for monobactams and are not inhibited by clavulanic acid or tazobactam. The most common metallo-beta-lactamase families include the IMP, VIM and NDM.
Antibiotic resistance to fluoroquinolones

All Enterobacteriaceae are naturally susceptible to fluoroquinolones. The process by which susceptible strains become highly fluoroquinolone resistant is thought to be a result of a series of sequential steps and several mutations are needed to produce a high level of fluoroquinolone resistance. High-level resistance emerges after successive chromosomal mutations in the DNA gyrase-encoding gyrA gene and topoisomerase IV-encoding parC gene. The over-expression of efflux pumps may also play a role in the high level of resistance in certain strains. Resistance to fluoroquinolones can also be mediated by the plasmid-encoded qnr genes, which confer protection of bacterial topoisomerases against fluoroquinolones, the plasmid-encoded efflux pump qepA.

Antibiotic resistance to aminoglycosides

Aminoglycosides resistance occurs through several mechanisms that can simultaneously coexist. Aminoglycosides resistance in Enterobacteriaceae relies mainly on the genes encoding aminoglycoside-modifying enzymes (AMEs). AMEs hamper antibiotic activity. AMEs are often located on plasmids that carry multiple resistance genes, including ESBL. Other described mechanisms of resistance include modification of the antibiotic target by mutation of the 16S rRNA or ribosomal proteins, methylation of 16S rRNA (by RNA methylases which genes are often co-located with beta-lactamase encoding genes), reduced permeability and/or increasing active efflux of the antibiotic.
Antibiotic resistance in non-fermenting Gram-negative bacteria
Non-fermenting Gram-negative bacteria (*P. aeruginosa*, *S. maltophilia* and *A. baumannii*) are intrinsically resistant to many drugs and can acquire resistance to virtually any antimicrobial agent. A variety of resistance mechanisms have been identified in *P. aeruginosa* and other Gram-negative non-fermenting bacteria, including impermeable outer membranes, expression of efflux pumps, target alteration and production of antibiotic-hydrolyzing enzymes such as AmpC beta-lactamases that are either chromosomally encoded or acquired. These mechanisms may be present simultaneously, conferring multiresistance to different classes of antibiotics. These mechanisms may also allow transmission to multiple strains of bacteria. *P. aeruginosa* is intrinsically resistant to a number of beta-lactam antibiotics including amoxicillin, first and second generation cephalosporins, cefotaxime, ceftriaxone and ertapenem. Effective agents include ticarcillin, piperacillin, ceftazidime, cefepime, imipenem, meropenem and doripenem. Aztreonam activity is variable. Unlike tazobactam, clavulanate is a strong inducer of AmpC in *P. aeruginosa*. *P. aeruginosa* also has the ability to acquire beta-lactamases, including ESBL and carbapenemases.

The *P. aeruginosa* genome contains several different multidrug resistance efflux pumps, which reside in the membrane and remove antimicrobials and toxins, thereby lowering their concentration inside the cell to sub-toxic levels. Overproduction of these pumps reduces susceptibility to a variety of antibiotics. The most common system is MexAB-OprM. Its overexpression confers resistance to ticarcillin, aztreonam, and at a lesser extent, meropenem. Reduced outer-membrane permeability caused by qualitative or quantitative alterations of the OprD porin, which manages the passage of imipenem through the outer membrane, confers *P. aeruginosa* a basal level of resistance to carbapenems, especially to imipenem.
The mechanisms of AMR in *A. baumannii* are various, and generally include production of beta-lactamases, impermeable outer membrane, expression of efflux pumps, and change of targets or cellular functions such as alterations in penicillin-binding proteins (PBPs). The PBPs play a crucial role in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. *A. baumannii* naturally produces a non-inducible AmpC-type cephalosporinase (ACE-1 or ACE-2) and an OXA-51-like carbapenemase which confers, at basal levels of expression, intrinsic resistance to aminopenicillins, first and second generation cephalosporins and aztreonam. Ertapenem naturally lacks activity against non-fermenting Gram negative bacteria including *A. baumannii*. Overproduction of the AmpC-type cephalosporinase confers acquired resistance to carboxypenicillins, ureidopenicillins and third generation cephalosporins. The emergence of carbapenem-resistant clones of *A baumannii* has been reported since the late 1980s. Carbapenem resistance can result from the over-expression of OXA-51-like oxacillinase, and from the acquisition of OXA-23-like, IMP, VIM, SIM or, more recently, NDM-type carbapenemases. Acquired resistances to fluoroquinolones (mutations in gyrA and/or parC) and aminoglycosides (plasmid-borne AMEs) may be observed in ESBL as well as carbapenemase-producing *A. baumannii* strains. Colistin resistant isolates are now increasing worldwide. Resistance to colistin is thought to be mediated by modifications of the lipopolysaccharides of the bacterial cell membrane that interfere with the agent’s ability to bind bacterial targets.
New antibiotics against Gram-negative bacteria
In recent years, several new antibiotics with predominant activity against Gram-negative bacteria have been approved by the U.S. Food and Drug Administration (FDA) and the European Medical Agency (EMA).

Eravacycline is an antibiotic that is structurally similar to tigecycline. Eravacycline demonstrates broad-spectrum activity against Gram-positive, Gram-negative—including anaerobic bacteria. Like tigecycline, it is inactive against *P. aeruginosa*. Eravacycline is well-tolerated with nausea and vomiting and, interestingly, is also available for oral administration.

Meropenem-vaborbactam, ceftazidime-avibactam, and imipenem-cilastatin-relebactam are the main options for *K. pneumoniae* carbapenemases-producing infections. Ceftazidime-avibactam is the preferred treatment option for OXA-48-like-producing *Enterobacterales*. Ceftazidime-avibactam in combination with aztreonam, or cefiderocol as monotherapy, are preferred treatment options for MBL-producing *Enterobacterales*.

Due to its epithelial lining fluid penetration, meropenem-vaborbactam should be used as first therapeutic choice in patients with ventilator-associated pneumonia due to KPC-producing *Enterobacterales*.

The lack of in vitro activity of ceftazidime-avibactam against metallo-beta-lactamase (MBL) and the observation that many MBL-producing infections can coproduce other beta-lactamases including ESBLs, AmpC, OXA-48, have suggested a potential effect of combining ceftazidime-avibactam with aztreonam, that is not hydrolyzed by MBLs. Cefiderocol appears to be effective in vitro against all resistance phenotypes of *P. aeruginosa*, including MBLs. Cefiderocol is also effective in vitro against difficult-to-treat resistant *A. baumannii*. Despite these promising early data, a recent clinical trial did not support the higher effectiveness of cefiderocol in severe infections due to difficult-to-treat resistant bacteria in critically ill subjects.

...
Possible applications of new antibiotics against Gram-negative bacteria based on resistant mechanisms.

<table>
<thead>
<tr>
<th></th>
<th>ESBL and AmpC</th>
<th>KPC</th>
<th>OXA-48</th>
<th>MBL</th>
<th>Carbapenem Non susceptible A. baumanii</th>
<th>Carbapenem Non susceptible P. aeruginosa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plazomicin</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+/- a</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Eravacycline</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+ b</td>
<td>++</td>
<td>–</td>
</tr>
<tr>
<td>Cefiderocol</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Ceftazidime/ avibactam</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>–</td>
<td>–</td>
<td>+/-</td>
</tr>
<tr>
<td>Ceftolozane/ tazobactam</td>
<td>++</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+/- c</td>
</tr>
<tr>
<td>Meropenem/ vaborbactam</td>
<td>++</td>
<td>++</td>
<td>–</td>
<td>–</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Imipenem/ relebactam</td>
<td>++</td>
<td>++</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+/- d</td>
</tr>
</tbody>
</table>

++: Activity (>90% of the isolates); +: activity in 70 to 90% of the isolates; +/-: activity in around the half of the; –: no activity; ?: no surveillance data available.  

a 42.1% susceptible isolates; b 70% susceptible isolates; c good activity against isolates with elevated efflux, derepressed AmpC or loss of OprD, but not when the underlying mechanism is MBL production; d not for isolates with class B or D carbapenemase activity.
Antibiotic resistance in enterococci
Enterococci are intrinsically resistant to some penicillins, all cephalosporins, and, at a low level, to aminoglycosides. Additionally, they have acquired resistance to many other classes of antibiotics. Enterococci have intrinsic resistance to most beta-lactam antibiotics because of the low affinity penicillin binding proteins (PBPs). Attachment of beta-lactam agents to PBPs results in impaired cell wall synthesis and, in most cases, programmed cell death via creation of reactive oxygen species. Enterococci express low-affinity PBPs (PBP5 in *E. faecium*, PBP4 in *E. faecalis*) that bind weakly to beta-lactam antibiotics. Enterococci may develop increased resistance to penicillins through acquisition of beta-lactamases (very rare) or PBP4/5 mutations. Higher level of resistance in *E. faecium* has been attributed to over production of low affinity PBP-5, a protein that can take over the function of all PBPs. In addition, enterococci are “tolerant” to the activity of beta-lactams, and may appear susceptible in vitro but develop tolerance after exposure to penicillin. This property is an acquired characteristic. Enterococci quickly develop tolerance after exposure to as few as five doses of penicillin.

Enterococci exhibit intrinsic low-level resistance to all aminoglycosides, precluding their use as single agents. Intrinsic resistance is attributed to an inability of the aminoglycoside to enter the cell (where they act by inhibiting ribosomal protein synthesis). While intrinsic mechanisms result in low-level aminoglycoside resistance, acquisition of mobile genetic elements typically underlies high-level aminoglycoside resistance in both *E. faecium* and *E. faecalis*. High-level resistance most frequently occurs through acquisition of a bifunctional gene encoding aph(2′′)-Ia-aac(6′)-Ie, which inactivates aminoglycosides. However, several other genes have been identified that confer gentamicin resistance, including aph(2′′)-Ic, aph(2′′)-Id and aph(2′′)-Ib. These genes are minor contributors to resistance compared to aph(2′′)-Ia-aac(6′)-Ie.

Their prevalence varies by geographical region. The acquisition of glycopeptides resistance by enterococci has seriously affected the treatment and control of these organisms. Glycopeptides act by binding to the pentapeptide precursors of enterococci, thereby inhibiting cell wall synthesis. Glycopeptide-resistant organisms modify these pentapeptide precursors, which bind glycopeptides with 1000-fold lower affinity than normal precursors. Various phenotypes of vancomycin-resistant enterococci (VRE) have been characterized; VanA and VanB operons are by far the most prevalent in human glycopeptide-resistant enterococci (GRE) infections. GRE have emerged as a major cause of nosocomial infections. The majority of GRE infections have been attributed to *E. faecium*, though glycopeptide resistance occurs in *E. faecalis* and other *Enterococcus* species as well.
The incidence of vancomycin-resistant E. faecium (VRE) is increasing. The acquisition of glycopeptide resistance by enterococci can seriously affect the treatment and control of these organisms in patients with hospital-acquired infections. Tigecycline, linezolid, and daptomycin still remain active against enterococcal isolates and can be used for the treatment of enterococcal infections worldwide. Obviously, monitoring of the rising resistance of VRE to these agents, appropriate antibiotic-resistance testing programs, and adequate antibiotic stewardship are extremely important in the successful reduction of resistance to the mentioned antibiotics, especially in VRE isolates.
Antibiotic resistance in *Staphylococcus aureus*
*Staphylococcus aureus* is a major human pathogen worldwide. Methicillin-resistant *S. aureus* (MRSA) poses a significant and enduring problem to the treatment of infection by such strains. Resistance is usually conferred by the acquisition of a nonnative gene encoding a penicillin binding protein (PBP2a), with significantly lower affinity for beta-lactams. This resistance allows cell-wall biosynthesis, the target of beta-lactams, to continue even in the presence of typically inhibitory concentrations of antibiotic. PBP2a is encoded by the *mecA* gene, which is carried on a distinct mobile genetic element (SCCmec), the expression of which is controlled through a proteolytic signal transduction pathway comprising a sensor protein (*MecR1*) and a repressor (*MecI*).

*S. aureus* strains exhibiting increased resistance to vancomycin, known as vancomycin intermediate-resistant *S. aureus* (VISA) were discovered in the 1990s. The molecular basis of resistance in VISA is polygenic and involves stepwise mutations in genes encoding molecules predominantly involved in cell envelope biosynthesis. *S. aureus* isolates with complete resistance to vancomycin (MIC \( \geq 16 \ \mu g/mL \)) are termed vancomycin-resistant *S. aureus* (VRSA)—they were first reported at the beginning of 2000s. Complete vancomycin resistance in *S. aureus* is conferred by the vanA operon encoded on transposon Tn1546, originally a part of a vancomycin-resistant enterococci (VRE) conjugative plasmid *S. aureus* can acquire enterococcal plasmids during discrete conjugation events. Vancomycin resistance in *S. aureus* is maintained by retaining an original enterococcal plasmid or by a transposition of Tn1546 from the VRE plasmid into a staphylococcal resident plasmid.

Glycopeptides such as vancomycin may be used to provide therapy for suspected or proven infections caused by vancomycin-susceptible MRSA. *S. aureus* strains with increased resistance to vancomycin—known as vancomycin-intermediate-resistant *S. aureus* (VISA), exhibiting an MIC of 4–8 \( \mu g/mL \), and *S. aureus* completely resistant to vancomycin (VRSA), exhibiting an MIC \( \geq 16 \ \mu g/mL \)—are increasing. Linezolid and daptomycin may be used for the management of suspected or proven infections caused by VRSA.
Long-Acting Lipoglycopeptides

The long-acting lipoglycopeptides (LGPs) dalbavancin and oritavancin are semisynthetic antimicrobials with broad and potent activity against Gram-positive bacterial pathogens.

While these agents have a similar spectrum to glycopeptides (e.g., vancomycin), they exhibit higher potency for most target pathogens. More importantly, they have much longer half-lives, allowing for reduced dosing frequencies (i.e., weekly) or even single-dose therapy. Consequently, there is great enthusiasm to use these drugs to facilitate hospital discharge and decrease the need for long-term intravascular catheters, especially for infections requiring prolonged antibiotic therapy, such as infective endocarditis, osteomyelitis, and prosthetic joint infections. However, the bulk of clinical evidence with long-acting LGPs, including all registrational trials, involves patients with acute bacterial skin and skin structure infections and not these more clinically pressing situations where LGPs are very interesting tools.
AWaRe classification
The AWaRe Classification of antibiotics was developed in 2017 by the WHO Expert Committee on Selection and Use of Essential Medicines as a tool to support antibiotic stewardship efforts at local, national and global levels. Antibiotics are classified into three groups, Access, Watch and Reserve, taking into account the impact of different antibiotics and antibiotic classes on antimicrobial resistance, to emphasize the importance of their appropriate use.

**Access**
Which indicates the antibiotic of choice for each of the 25 most common infections. These antibiotics should be available at all times, affordable and quality-assured.

**Watch**
Which includes most of the “highest-priority critically important antimicrobials” for human medicine and veterinary use. These antibiotics are recommended only for specific, limited indications.

**Reserve**
Antibiotics that should only be used as a last resort when all other antibiotics have failed.

The 2021 update of the AWaRe classification includes an additional 78 antibiotics not previously classified, bringing the total to 258. It is a useful tool for monitoring antibiotic consumption, defining targets and monitoring the effects of stewardship policies that aim to optimize antibiotic use and curb antimicrobial resistance. The WHO 13th General Programme of Work 2019–2023 includes a country-level target of at least 60% of total antibiotic consumption being Access group antibiotics.
References


Let’s act now

Awareness
Knowledge
Attitude
Better understanding of mechanisms of antibiotic resistance would allow the development of control strategies to reduce the spread of resistant bacteria and their evolution.